As the healthcare industry approaches significant changes, leaders from Red Cell Partners share insights on the anticipated overhaul of Medicaid, the rise of AI technology, and evolving medication management strategies.

As the healthcare industry prepares for transformative changes in the new year, leaders from Red Cell Partners, an investment and incubation firm based in McLean, Virginia, recently shared their insights on emerging trends with MedCity News. These trends are anticipated to significantly shape the landscape of healthcare in the coming years.

A major focal point in this discussion is the expected overhaul of Medicaid in 2025. Kunal Sethy, an entrepreneur in residence at Red Cell and head of Sparrow Healthcare, highlighted that these anticipated structural changes will be the most significant since the programme’s inception. Key adjustments will include the introduction of caps on federal cost sharing, block grants, and work requirements for beneficiaries. Sethy noted that these developments might reduce eligibility flexibility and place waiver programs at risk. “These changes will not all be phased in at once and will take time,” he explained. “However, they will undoubtedly lead to downward pressure on the overall Medicaid program, leading to fewer covered benefits and services and more consumers becoming uninsured.” This impending change could spur innovation among stakeholders including startups, regulators, legacy health plans, and state governments.

In a related trend, Naimish Patel, president of Red Cell’s healthcare practice, emphasised the rising adoption of AI agents within healthcare organisations. He observed that these tools are increasingly regarded as valuable assets that can assist providers in transitioning away from inefficient, manual processes and outdated technology. “AI agents are increasingly seen as creating disproportionate value for healthcare businesses,” Patel stated, noting their ability to autonomously handle administrative tasks, provide clinical decision support, and enhance patient engagement. Several healthcare startups such as Suki, Kairo Health, and Owkin are at the forefront of delivering these AI solutions.

Lastly, the approach to managing GLP-1 (glucagon-like peptide-1) medications is set to evolve, especially among employers. Borislava Marcheva, head of market engagement at Red Cell, predicted that employers would increasingly evaluate ways to meet the growing demand for GLP-1 treatments. She noted that while smaller organisations will mainly focus on coverage decisions, larger entities will likely engage in a more detailed analysis to determine which utilisation management techniques yield the best results. “We will see more open information sharing among employers, pharmacy benefit managers, navigators, and third-party vendors in an effort to manage GLP-1 spend,” Marcheva explained. This collaboration could lead to the development of meaningful frameworks to define optimal utilisation management solutions based on factors such as employee demographics, the prevalence of chronic diseases, healthcare consumption patterns, and regional dynamics.

These insights from Red Cell Partners underline a pivotal moment in healthcare, characterised by structural changes to Medicaid, the increased use of AI technology, and a refined approach to medication management, all of which promise to redefine the industry landscape in the near future.

Source: Noah Wire Services

More on this

Share.
Leave A Reply

Exit mobile version